Federal Register / Vol. 63, No. 131 /Thursday, July 9, 1998 / Notices 37139

which will be distributed to analytical

and forensic laboratories for drug testing

programs.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 8, 1998.

Dated; June 30, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18220 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on April 17, 1998, Radian

International LLC, 8501 North Mopac

Blvd., P.O. Box 201088, Austin, Texas

78720, made application to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below.

Drug Schedule

Cathinone (1235) .......................... I

Methcathinone (1237) ................... I

N-Ethylamphetamine (1475) ......... I

Ibogaine (7260) ............................ I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

Drug Schedule

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

2,5-Dimethoxy-4-

ethylamphetamine (7399).

I

3,4-Methylenedioxyamphetamine

(7400).

I

5-Methoxy-e,4-

methylenedioxyamphetamine

(7401).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

4-Methoxyamphetamine (7411) .... I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Etorphine (except HCl) (9056) ..... I

Heroin (9200) ................................ I

Pholcodine (9314) ........................ I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Meperidine (9230) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Levo-alphacetylmethadol (9648) .. II

Oxymorphone (9652) .................... II

The firm plans to import small

quantities of the listed controlled

substances for the manufacture of

analytical reference standards.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than August 10, 1998.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic class of any

controlled substance in Schedule I or II

are and will continue to be required to

demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: June 24, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18221 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on April 1,

1998, Research Biochemicals, Inc.,

which has changed its name to SigmaAldrich Research Biochemicals, Inc.,

One Three Strathmore Road, Attn:

Richard A. Milius PhD, Natick,

Massachusetts 01760, made application

by renewal to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below.

Drug Schedule

Cathinone (1235) .......................... I

Methcathinone (1237) ................... I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

2,5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine

(7400).

I

N-Hydroxy-3,4-

methylenedioxyamphetamine

(7402).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

1-[1-(2-

Thienyl)cyclohexyl]piperidine

(7470).

I

Heroin (9200) ................................ I

Methamphetamine (1105) ............ II

Phencyclidine (7471) .................... II

Benzoylecgonine (9180) ............... II
37140 Federal Register / Vol. 63, No. 131 /Thursday, July 9, 1998 / Notices

The firm plans to import small

quantities of the listed controlled

substance to manufacture laboratory

reference standards and

neurochemicals.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 8, 1998.

Dated: June 30, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18222 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on April 1, 1998, Research

Biochemicals, Inc., which has changed

its name to Sigma-Aldrich Research

Biochemicals, Inc., One Three

Strathmore Road, Attn: Richard A.

Milius PhD, Natick, Massachusetts

01760, made application to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Methaqualone (2565) ................... I

Ibogaine (7260) ............................ I

Tetrahydrocannabinols (7370) ...... I

Bufotenine (7433) ......................... I

Drug Schedule

Dimethyltryptamine (7435) ........... I

Etorphine (except HC1) (9056) .... I

Methylphenidate (1724) ................ II

Pentobarbital (2270) ..................... II

Diprenorphine (9058) .................... II

Etorphine Hydrochloride (99059) II

Diphenoxylate (9170) ................... II

Metazocine (9240) ........................ II

Methadone (9250) ........................ II

Fentanyl (9801) ............................ II

The firm plans to import small

quantities of the listed controlled

substances to manufacture laboratory

reference standards and

neurochemicals.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.54 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than August 10, 1998.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: June 24, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18223 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on March 31, 1998, Research

Triangle Institute, Kenneth H. Davis, Jr.,

Hermann Building, East Institute Drive,

P.O. Box 12194, Research Triangle Park,

North Carolina 27709, made application

by renewal to the Drug Enforcement

Administration to be registered as an

importer of the basic classes of

controlled substances listed below:

Drug Schedule

Marihuana (7360) ......................... I

Cocaine (9041) ............................. II

The firm plans to import small

quantities of the listed controlled

substances for the National Institute of

Drug Abuse and other clients.

Any manufacturer holding, or

applying, for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than August 10, 1998.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import the basic classes